• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

DEA wants to slash opioid production

News
Article

The Drug Enforcement Administration wants to slash the production of opioid painkillers by 20% in 2018.

The Drug Enforcement Administration (DEA) wants to slash the production of opioid painkillers by 20% in 2018.

In an August 7, 2017 Federal Register notice, DEA proposed reducing the more commonly prescribed schedule II opioid painkillers, including oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine, codeine, meperidine and fentanyl, by 20% compared to 2017.

Related: FDA to drug maker: Pull opioid pain drug

Demand for those painkillers has dropped, according to sales data obtained by DEA from IMS Health.

“Physicians, pharmacists, and patients must recognize the inherent risks of these powerful medications, especially for long-term use,” said DEA Acting Administrator Chuck Rosenberg, in a statement from the agency. “More states are mandating use of prescription drug monitoring programs, which is good, and that has prompted a decrease in opioid prescriptions.”

Related: Drug distributor pays record fine

When Congress passed the Controlled Substances Act, the quota system was intended to reduce or eliminate diversion from “legitimate channels of trade” by controlling the quantities of the basic ingredients needed for the manufacture of controlled substances, according to DEA.

“The purpose of quotas is to provide for an adequate and uninterrupted supply for legitimate medical need of schedule I and schedule II controlled substances, which have a high potential for abuse, while limiting the amounts available to prevent diversion,” DEA said.

Read more: DEA slashes opioid drug production

 

 

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.